First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

Topics: 

Citation
Marx N et al. Eur Heart J 2019; 40(Issue Supplement_1):ehz746.0871.